CRISPR-Cas9 base editors and their current role in human therapeutics

Walker S Lahr; Christopher J Sipe; Joseph G Skeate; Beau R. Webber; Branden S. Moriarity

doi:10.1016/j.jcyt.2022.11.013

CRISPR-Cas9 base editors and their current role in human therapeutics

Walker S Lahr, Christopher J Sipe, Joseph G Skeate, Beau R. Webber, Branden S. Moriarity

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Consistent progress has been made to create more efficient and useful CRISPR-Cas9-based molecular toolsfor genomic modification. Methods: This review focuses on recent articles that have employed base editors (BEs) for both clinical and research purposes. Results: CRISPR-Cas9 BEs are a useful system because of their highefficiency and broad applicability to gene correction and disruption. In addition, base editing has beensuggested as a safer approach than other CRISPR-Cas9-based systems, as it limits double-strand breaksduring multiplex gene knockout and does not require a toxic DNA donor molecule for genetic correction. Conclusion: As such, numerous industry and academic groups are currently developing base editing strategies withclinical applications in cancer immunotherapy and gene therapy, which this review will discuss, with a focuson current and future applications of in vivo BE delivery.

Original language	English (US)
Pages (from-to)	270-276
Number of pages	7
Journal	Cytotherapy
Volume	25
Issue number	3
DOIs	https://doi.org/10.1016/j.jcyt.2022.11.013
State	Published - Mar 2023

Bibliographical note

Funding Information:
CJS was funded by the University of Minnesota's Stem Cell Institute INFUSE pre-doctoral award. JGS is supported by the T32HL007062-46 Hematology Research Training Program. BRW acknowledges funding from the National Institutes of Health (grant nos. R21CA237789, R21AI163731 and P01CA254849), Alex's Lemonade Stand Foundation, Children's Cancer Research Fund and Rein in Sarcoma. BSM acknowledges funding from the National Institutes of Health (grant nos. R01AI161017, R01AI161017, P01CA254849 and P50CA136393), Children's Cancer Research Fund and Fanconi Anemia Research Fund.

Publisher Copyright:
© 2022

Keywords

base editor
cancer immunotherapy
gene therapy
hematopoietic stem cell
multiplex gene editing
sickle cell

PubMed: MeSH publication types

Review
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.jcyt.2022.11.013License: CC BY-NC-ND

Find It

Find It at U of M Libraries

Cite this

@article{d5c7cfb0b6414c48a34c0cbfc09132d7,

title = "CRISPR-Cas9 base editors and their current role in human therapeutics",

abstract = "Background: Consistent progress has been made to create more efficient and useful CRISPR-Cas9-based molecular toolsfor genomic modification. Methods: This review focuses on recent articles that have employed base editors (BEs) for both clinical and research purposes. Results: CRISPR-Cas9 BEs are a useful system because of their highefficiency and broad applicability to gene correction and disruption. In addition, base editing has beensuggested as a safer approach than other CRISPR-Cas9-based systems, as it limits double-strand breaksduring multiplex gene knockout and does not require a toxic DNA donor molecule for genetic correction. Conclusion: As such, numerous industry and academic groups are currently developing base editing strategies withclinical applications in cancer immunotherapy and gene therapy, which this review will discuss, with a focuson current and future applications of in vivo BE delivery.",

keywords = "base editor, cancer immunotherapy, gene therapy, hematopoietic stem cell, multiplex gene editing, sickle cell",

author = "Lahr, {Walker S} and Sipe, {Christopher J} and Skeate, {Joseph G} and Webber, {Beau R.} and Moriarity, {Branden S.}",

note = "Funding Information: CJS was funded by the University of Minnesota's Stem Cell Institute INFUSE pre-doctoral award. JGS is supported by the T32HL007062-46 Hematology Research Training Program. BRW acknowledges funding from the National Institutes of Health (grant nos. R21CA237789, R21AI163731 and P01CA254849), Alex's Lemonade Stand Foundation, Children's Cancer Research Fund and Rein in Sarcoma. BSM acknowledges funding from the National Institutes of Health (grant nos. R01AI161017, R01AI161017, P01CA254849 and P50CA136393), Children's Cancer Research Fund and Fanconi Anemia Research Fund. Publisher Copyright: {\textcopyright} 2022",

year = "2023",

month = mar,

doi = "10.1016/j.jcyt.2022.11.013",

language = "English (US)",

volume = "25",

pages = "270--276",

journal = "Cytotherapy",

issn = "1465-3249",

publisher = "Informa Healthcare",

number = "3",

}

TY - JOUR

T1 - CRISPR-Cas9 base editors and their current role in human therapeutics

AU - Lahr, Walker S

AU - Sipe, Christopher J

AU - Skeate, Joseph G

AU - Webber, Beau R.

AU - Moriarity, Branden S.

N1 - Funding Information: CJS was funded by the University of Minnesota's Stem Cell Institute INFUSE pre-doctoral award. JGS is supported by the T32HL007062-46 Hematology Research Training Program. BRW acknowledges funding from the National Institutes of Health (grant nos. R21CA237789, R21AI163731 and P01CA254849), Alex's Lemonade Stand Foundation, Children's Cancer Research Fund and Rein in Sarcoma. BSM acknowledges funding from the National Institutes of Health (grant nos. R01AI161017, R01AI161017, P01CA254849 and P50CA136393), Children's Cancer Research Fund and Fanconi Anemia Research Fund. Publisher Copyright: © 2022

PY - 2023/3

Y1 - 2023/3

N2 - Background: Consistent progress has been made to create more efficient and useful CRISPR-Cas9-based molecular toolsfor genomic modification. Methods: This review focuses on recent articles that have employed base editors (BEs) for both clinical and research purposes. Results: CRISPR-Cas9 BEs are a useful system because of their highefficiency and broad applicability to gene correction and disruption. In addition, base editing has beensuggested as a safer approach than other CRISPR-Cas9-based systems, as it limits double-strand breaksduring multiplex gene knockout and does not require a toxic DNA donor molecule for genetic correction. Conclusion: As such, numerous industry and academic groups are currently developing base editing strategies withclinical applications in cancer immunotherapy and gene therapy, which this review will discuss, with a focuson current and future applications of in vivo BE delivery.

AB - Background: Consistent progress has been made to create more efficient and useful CRISPR-Cas9-based molecular toolsfor genomic modification. Methods: This review focuses on recent articles that have employed base editors (BEs) for both clinical and research purposes. Results: CRISPR-Cas9 BEs are a useful system because of their highefficiency and broad applicability to gene correction and disruption. In addition, base editing has beensuggested as a safer approach than other CRISPR-Cas9-based systems, as it limits double-strand breaksduring multiplex gene knockout and does not require a toxic DNA donor molecule for genetic correction. Conclusion: As such, numerous industry and academic groups are currently developing base editing strategies withclinical applications in cancer immunotherapy and gene therapy, which this review will discuss, with a focuson current and future applications of in vivo BE delivery.

KW - base editor

KW - cancer immunotherapy

KW - gene therapy

KW - hematopoietic stem cell

KW - multiplex gene editing

KW - sickle cell

UR - http://www.scopus.com/inward/record.url?scp=85146137293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85146137293&partnerID=8YFLogxK

U2 - 10.1016/j.jcyt.2022.11.013

DO - 10.1016/j.jcyt.2022.11.013

M3 - Article

C2 - 36635153

AN - SCOPUS:85146137293

SN - 1465-3249

VL - 25

SP - 270

EP - 276

JO - Cytotherapy

JF - Cytotherapy

IS - 3

ER -

CRISPR-Cas9 base editors and their current role in human therapeutics

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this